Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cellular communication network factor 2 (CCN2), historically known as connective tissue growth factor (CTGF), is a cysteine-rich, secreted matricellular protein belonging to the CCN family. It plays a pivotal role in coordinating cellular responses to the extracellular matrix by interacting with various cell surface receptors, including integrins, heparan sulfate proteoglycans (HSPGs), and low-density lipoprotein receptor-related proteins (LRPs), as well as growth factors like TGF-beta and VEGF. CCN2 is a critical mediator of tissue remodeling, wound healing, and fibrogenesis, and its aberrant overexpression is strongly associated with progressive fibrotic diseases (such as idiopathic pulmonary fibrosis and diabetic nephropathy), cardiovascular diseases, and various malignancies. Consequently, CCN2 has been a major therapeutic target for anti-fibrotic drug development. Therapeutic strategies have included monoclonal antibodies (e.g., pamrevlumab), RNA interference therapeutics (e.g., RXI-109), and inhaled Anticalin proteins (e.g., PRS-220). However, clinical translation has faced significant hurdles, with systemic inhibitors like pamrevlumab failing in Phase III trials for idiopathic pulmonary fibrosis and Duchenne muscular dystrophy, often attributed to poor tissue penetration and target-mediated drug disposition.
Monoclonal antibody binding to the von Willebrand factor type C (vWC) domain of CTGF, preventing its interaction with TGF-beta and other cytokines; RNA interference (RNAi) mediated knockdown of CTGF mRNA to reduce protein expression; Anticalin protein binding and neutralizing extracellular CTGF; Aptamer binding to the C-terminal (CT) domain of CTGF to inhibit its fibrotic activity.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular communication network factor 2 (CCN2).